BioSpace News Archive

Little Spurs Pediatric Urgent Care, a highly regarded pediatric urgent care provider with 13 clinics around San Antonio, New Braunfels and Dallas, announces the addition of telemedicine and enhanced measures to make all clinics safe for both patients and staff members.

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2020 on Thursday, April 30, 2020, after the New York Stock Exchange closes.

Stockholders elected Samuel R. Allen, Ajay Banga, Jacqueline K. Barton, James A. Bell, Wesley G. Bush, Richard K. Davis, Jeff M. Fettig, Jim Fitterling, Jacqueline C. Hinman, Jill S. Wyant, and Daniel W. Yohannes to the Company’s Board of Directors for one-year terms.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted thirteen new employees options to purchase a total of 381,200 shares of the Company’s common stock at an exercise price per share of $15.32, which was the closing price on April 8, 2020.

Company to provide FDA-approved for EUA testing in its San Diego lab to assist physician clients in the fight against the coronavirus pandemic

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a business update related to the COVID-19 pandemic.

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that the United States Patent Office issued U.S. Patent No. 10,597,443 with an expiry of May 2034.

Fulgent Genetics, Inc., a provider of comprehensive genetic testing and Next Generation Sequencing solutions, announced that it is offering end-to-end processing, analysis and reporting for its recently launched COVID-19 tests.

AXON Neuroscience (“Axon”), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases, is developing a promising vaccine candidate against COVID-19. Axon has over 20 years’ experience in development of safe and immunogenic peptide vaccines. Its well-established

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases, at Weill Cornell Medicine.